CN116194479B - 抗tau抗体 - Google Patents

抗tau抗体

Info

Publication number
CN116194479B
CN116194479B CN202180062368.9A CN202180062368A CN116194479B CN 116194479 B CN116194479 B CN 116194479B CN 202180062368 A CN202180062368 A CN 202180062368A CN 116194479 B CN116194479 B CN 116194479B
Authority
CN
China
Prior art keywords
seq
amino acid
set forth
sequence set
specific binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180062368.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN116194479A (zh
Inventor
查尔斯·R·哈林顿
S·帕利里·索曼
A·J·R·波特
克劳德·M·维希克
M·阿拉斯托
L·K·潘妮
R·洛夫特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gt Innovation Co
Original Assignee
Gt Innovation Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gt Innovation Co filed Critical Gt Innovation Co
Publication of CN116194479A publication Critical patent/CN116194479A/zh
Application granted granted Critical
Publication of CN116194479B publication Critical patent/CN116194479B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180062368.9A 2020-07-10 2021-07-09 抗tau抗体 Active CN116194479B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2010652.2 2020-07-10
GBGB2010652.2A GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies
PCT/EP2021/069160 WO2022008719A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies

Publications (2)

Publication Number Publication Date
CN116194479A CN116194479A (zh) 2023-05-30
CN116194479B true CN116194479B (zh) 2026-05-22

Family

ID=72140057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062368.9A Active CN116194479B (zh) 2020-07-10 2021-07-09 抗tau抗体

Country Status (10)

Country Link
US (1) US12624096B2 (enExample)
EP (1) EP4178980A1 (enExample)
JP (1) JP7796719B2 (enExample)
KR (1) KR20230038721A (enExample)
CN (1) CN116194479B (enExample)
AU (1) AU2021306653A1 (enExample)
CA (1) CA3185175A1 (enExample)
GB (1) GB202010652D0 (enExample)
TW (1) TWI912331B (enExample)
WO (1) WO2022008719A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4463480A1 (en) * 2022-01-12 2024-11-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample
WO2023135201A1 (en) * 2022-01-12 2023-07-20 Gtinvent Limited Method for detecting a tau protein fragment in a sample

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015004163A1 (en) * 2013-07-08 2015-01-15 Adx Neurosciences Anti-tau monoclonal antibodies
WO2018031361A2 (en) * 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
CN110290801A (zh) * 2016-12-07 2019-09-27 基因泰克公司 抗tau抗体和使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
DK2853293T3 (en) 2006-03-29 2018-01-22 Wista Lab Ltd Thioninium compounds and their use
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
KR101231777B1 (ko) 2010-11-25 2013-02-08 부산대학교 산학협력단 ＧＳＫ３β 저해를 통한 타우 과인산화 저해제 탐색 방법
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
JP6284548B2 (ja) * 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
US20200030445A1 (en) 2015-06-12 2020-01-30 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN117205311A (zh) * 2017-03-28 2023-12-12 基因泰克公司 治疗神经退行性疾病的方法
CN120305401A (zh) * 2018-10-19 2025-07-15 总医院公司 用于肝病的治疗的组合物和方法
EP4463480A1 (en) * 2022-01-12 2024-11-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015004163A1 (en) * 2013-07-08 2015-01-15 Adx Neurosciences Anti-tau monoclonal antibodies
WO2018031361A2 (en) * 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
CN110290801A (zh) * 2016-12-07 2019-09-27 基因泰克公司 抗tau抗体和使用方法

Also Published As

Publication number Publication date
US20230257452A1 (en) 2023-08-17
EP4178980A1 (en) 2023-05-17
CN116194479A (zh) 2023-05-30
KR20230038721A (ko) 2023-03-21
WO2022008719A1 (en) 2022-01-13
US12624096B2 (en) 2026-05-12
JP7796719B2 (ja) 2026-01-09
TWI912331B (zh) 2026-01-21
TW202214686A (zh) 2022-04-16
CA3185175A1 (en) 2022-01-13
GB202010652D0 (en) 2020-08-26
JP2023533768A (ja) 2023-08-04
AU2021306653A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US10208111B2 (en) Alpha-synuclein antibodies and uses thereof
EP3160998B1 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
RU2760875C1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
CN107847595A (zh) 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
JP2021515556A (ja) 抗ｐｈｆ−タウ抗体及びその使用
CN116194479A (zh) 抗tau抗体
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
US20230365665A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
US11472869B2 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
RU2855123C1 (ru) Антитела против тау
TW202344840A (zh) 診斷檢定
EA039569B1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant